vs
Side-by-side financial comparison of BLACKBERRY Ltd (BB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $141.8M, roughly 1.3× BLACKBERRY Ltd). BLACKBERRY Ltd runs the higher net margin — 9.7% vs 1.6%, a 8.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -0.8%). Over the past eight quarters, BLACKBERRY Ltd's revenue compounded faster (17.8% CAGR vs -0.2%).
BlackBerry Limited, formerly Research In Motion (RIM), is a Canadian software company specializing in secure communications and the Internet of Things (IoT). Founded in 1984, it developed the BlackBerry brand of two-way pagers, smartphones, and tablets. The company later transitioned to providing software and services and holds critical software application patents.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BB vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $141.8M | $177.4M |
| Net Profit | $13.7M | $2.9M |
| Gross Margin | 77.5% | — |
| Operating Margin | 8.4% | 3.9% |
| Net Margin | 9.7% | 1.6% |
| Revenue YoY | -0.8% | 5.0% |
| Net Profit YoY | 224.5% | — |
| EPS (diluted) | $0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $141.8M | $196.9M | ||
| Q3 25 | $129.6M | $179.5M | ||
| Q2 25 | $121.7M | $181.1M | ||
| Q1 25 | $141.7M | $168.9M | ||
| Q4 24 | $143.6M | $187.3M | ||
| Q3 24 | $126.2M | $168.6M | ||
| Q2 24 | $123.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $13.7M | — | ||
| Q3 25 | $13.3M | $5.4M | ||
| Q2 25 | $1.9M | $-4.8M | ||
| Q1 25 | $-7.4M | $4.8M | ||
| Q4 24 | $-10.5M | — | ||
| Q3 24 | $-19.7M | $-143.5M | ||
| Q2 24 | $-41.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 77.5% | 79.5% | ||
| Q3 25 | 74.5% | 80.9% | ||
| Q2 25 | 74.2% | 77.4% | ||
| Q1 25 | 73.5% | 79.7% | ||
| Q4 24 | 78.1% | 78.7% | ||
| Q3 24 | 70.2% | 76.9% | ||
| Q2 24 | 72.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 8.4% | 1.2% | ||
| Q3 25 | 8.9% | 3.5% | ||
| Q2 25 | 1.6% | 4.7% | ||
| Q1 25 | -5.6% | 1.2% | ||
| Q4 24 | 13.6% | 13.2% | ||
| Q3 24 | 1.7% | -82.8% | ||
| Q2 24 | -10.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 9.7% | — | ||
| Q3 25 | 10.3% | 3.0% | ||
| Q2 25 | 1.6% | -2.7% | ||
| Q1 25 | -5.2% | 2.8% | ||
| Q4 24 | -7.3% | — | ||
| Q3 24 | -15.6% | -85.1% | ||
| Q2 24 | -33.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.02 | $0.05 | ||
| Q3 25 | $0.02 | $0.12 | ||
| Q2 25 | $0.00 | $-0.11 | ||
| Q1 25 | $-0.01 | $0.10 | ||
| Q4 24 | $-0.02 | $0.38 | ||
| Q3 24 | $-0.03 | $-3.11 | ||
| Q2 24 | $-0.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $304.2M | $144.3M |
| Total DebtLower is stronger | $196.2M | — |
| Stockholders' EquityBook value | $741.1M | $653.9M |
| Total Assets | $1.2B | $1.2B |
| Debt / EquityLower = less leverage | 0.26× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $304.2M | $238.4M | ||
| Q3 25 | $290.5M | $246.3M | ||
| Q2 25 | $306.6M | $445.9M | ||
| Q1 25 | $337.8M | $493.6M | ||
| Q4 24 | $220.0M | $484.6M | ||
| Q3 24 | $211.0M | $453.8M | ||
| Q2 24 | $229.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $196.2M | $372.2M | ||
| Q3 25 | $195.9M | $376.7M | ||
| Q2 25 | $195.6M | $580.5M | ||
| Q1 25 | $195.3M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $741.1M | $693.1M | ||
| Q3 25 | $725.1M | $727.2M | ||
| Q2 25 | $725.1M | $757.8M | ||
| Q1 25 | $719.9M | $798.5M | ||
| Q4 24 | $725.2M | $778.3M | ||
| Q3 24 | $732.1M | $749.6M | ||
| Q2 24 | $742.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.26× | 0.54× | ||
| Q3 25 | 0.27× | 0.52× | ||
| Q2 25 | 0.27× | 0.77× | ||
| Q1 25 | 0.27× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.3M | — |
| Free Cash FlowOCF − Capex | $17.4M | — |
| FCF MarginFCF / Revenue | 12.3% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | $42.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $18.3M | $43.7M | ||
| Q3 25 | $3.9M | $60.8M | ||
| Q2 25 | $-18.0M | $12.0M | ||
| Q1 25 | $41.6M | $35.5M | ||
| Q4 24 | $6.0M | $33.1M | ||
| Q3 24 | $-16.0M | $53.9M | ||
| Q2 24 | $-15.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $17.4M | $43.5M | ||
| Q3 25 | $3.1M | $57.0M | ||
| Q2 25 | $-18.9M | $9.3M | ||
| Q1 25 | $41.2M | $26.9M | ||
| Q4 24 | $5.2M | $31.0M | ||
| Q3 24 | $-16.5M | $49.8M | ||
| Q2 24 | $-16.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 12.3% | 22.1% | ||
| Q3 25 | 2.4% | 31.7% | ||
| Q2 25 | -15.5% | 5.1% | ||
| Q1 25 | 29.1% | 15.9% | ||
| Q4 24 | 3.6% | 16.6% | ||
| Q3 24 | -13.1% | 29.6% | ||
| Q2 24 | -13.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 0.1% | ||
| Q3 25 | 0.6% | 2.2% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.3% | 5.1% | ||
| Q4 24 | 0.6% | 1.1% | ||
| Q3 24 | 0.4% | 2.4% | ||
| Q2 24 | 1.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 0.29× | 11.20× | ||
| Q2 25 | -9.47× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BB
| QNX | $68.7M | 48% |
| Secure Communication | $67.0M | 47% |
| Licensing | $6.1M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
